Medtronic Launches PulseSelect Pulsed Field Ablation System in India for Cardiac Care

Medtronic has introduced the PulseSelect Pulsed Field Ablation (PFA) system to the Indian market, extending a cardiac electrophysiology platform that has already cleared regulatory pathways in other major geographies. For device manufacturers and QA leads operating in the cardiac space, the launch signals a broadening commercial footprint for PFA technology in a high-volume emerging market.

Pulsed field ablation delivers non-thermal energy to isolate pulmonary veins in patients with atrial fibrillation, a mechanism designed to reduce collateral tissue damage associated with conventional thermal ablation techniques. The PulseSelect system's entry into India follows its earlier approvals in the United States and Europe, where it competes in a rapidly expanding segment of the electrophysiology device market.

For regulatory affairs leads tracking India's CDSCO device approval landscape, the clearance reflects continued alignment between India's medical device regulatory framework and international standards, a trajectory reinforced by the India-France Innovation Roadmap 2030, which identifies AI-driven healthcare, biomedical research, and life sciences as priority cooperation areas between the two nations. That bilateral framework could accelerate future device and pharma approvals by deepening data-sharing and joint research infrastructure.

Distribution and post-market surveillance obligations under India's Medical Devices Rules will govern how Medtronic manages the PulseSelect rollout domestically, including adverse event reporting timelines and import licensing requirements. Facilities handling or servicing the system will need to confirm their quality management systems are calibrated to those requirements ahead of clinical deployment.

The broader India-France cooperation agenda, running parallel to this launch, positions India as an increasingly active node in global health innovation networks, with implications for both inbound device launches and outbound pharmaceutical manufacturing partnerships.

The measurable near-term checkpoint is Medtronic's post-market clinical follow-up data from Indian centres, which will inform both local regulatory standing and the global evidence base for PFA as a standard-of-care intervention in atrial fibrillation.

Source: Media4Growth via Indian Pharma Post, 14 June 2026.